// App-Quantinova.ai

3503 : NCI9673: A multi-institutional eETCTN phase II study of nivolumab in refractory metastatic squamous cell carcinoma of the anal canal (SCCA).

Researchers

Presenter

  • Van Karlyle Morris

Principal Investigators

  • Mohamed E. Salem

  • Halla Sayed Nimeiri

  • Syma Iqbal

  • Preet Paul Singh

  • Blase N. Polite

  • Dustin A. Deming

  • Emily Chan

  • James Lloyd Wade

  • Tanios S. Bekaii-Saab

  • Hope Elizabeth Uronis

  • Manolo G Pasia

  • Gail Bland

  • Robert A. Wolff

  • Aki Ohinata

  • Chimela Ohaji

  • Jane Rogers

  • Padmanee Sharma

  • Cathy Eng

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital, Columbus, OH

  • Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC

  • Robert H. Lurie Cancer Center of Northwestern University, Chicago, IL

  • University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA

  • Mayo Clinic, Rochester, Rochester, MN

  • The University of Chicago Medical Center, Chicago, IL

  • University of Wisconsin Hosp and Clinics, Madison, WI

  • Vanderbilt University Medical Center, Nashville, TN

  • Cancer Care Center of Decatur, Decatur, IL

  • The Ohio State University Comprehensive Cancer Center, Columbus, OH

  • Duke University Medical Center, Durham, NC

  • Clinical Research Support Center, The University of Texas MD Anderson Cancer Center, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Squamous cell carcinoma

  • Hepatitis B

  • Solid malignancies

Biomarkers

  • Cluster of Differentiation 4

  • Programmed death-ligand 1

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • Multicenteric

Phase

  • II

Study Id's

  • NCI9673

  • NCT02314169

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved